Public information according to the provisions of Directive 2001/18/EC
File:
Trial reference:
A phase 2, single-blinded, randomized, controlled multi-country study to evaluate the safety,reactogenicity, efficacy and immune response following sequential treatment with an antisense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by
Doc type: